LP
VIRX

LMR Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

LMR Partners’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,931
Closed -$55K – 1312
2022
Q3 		$55K Hold
12,931
– – ﹤0.01% 1090
2022
Q2 		$50K Buy
+12,931
New +$36.8K ﹤0.01% 1163
2015
Q3 		– Sell
-232
Closed -$147K – 515
2015
Q2 		$147K Buy
+232
New +$123K 0.02% 418
2014
Q4 		– Sell
-164
Closed -$246K – 482
2014
Q3 		$246K Buy
+164
New +$237K 0.02% 235
2014
Q2 		– Sell
-158
Closed -$219K – 581
2014
Q1 		$219K Buy
+158
New +$184K 0.03% 218

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LMR Partners's VIRX Position: Q4 2022 in Review

LMR Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2022, closing a stake of 12,931 shares — an estimated $55K sold.

LMR Partners first reported a position in VIRX in Q1 2014 and held it in 5 quarters. The position peaked at $246K in Q3 2014. 56 funds tracked by Wall St. Rank hold VIRX as of Q4 2022.

  • LMR Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 12,931 Viracta Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $55K.
  • LMR Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 5 quarters.
  • LMR Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $246K in Q3 2014.
  • 56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.